Attention Deficit Hyperactivity Disorder (ADHD) has been recognized as one of the most common disorders across the globe, beginning as early as age six and progressing to adolescence and adult life. It is a mental condition that affects an estimated four million children and adolescents in the United States alone. Some of its common symptoms include being easily distracted, missing details, forgetting things or being overly restless, lack of focus and attention, and being impatient, among many others. Although causes of such a mental disorder are still unknown to scientists and researchers, many studies attribute genes and environment as major factors, among others.
Currently available treatments cannot cure the disorder per se. Instead, they focus on reducing the symptoms of ADHD and improving the individual’s functioning. Treatments include medication, various types of psychotherapy, education or training, or a combination of treatments. Researchers are developing more effective treatments and interventions, and using new tools such as brain imaging, to better understand ADHD and to find more effective ways to treat and prevent it.
Being a psychological disorder, this disorder impacts every aspect of the individual including academic difficulties, social skills problems and parent-child relationships. Therefore, proper behavioural therapy and medication, an environment that is sensitive to the needs of an individual with ADHD, and being aware of the implications of the disorder is vital.
One of the success stories in this context is, undoubtedly, that of Michael Phelps (1985 – present), winner of 22 Olympic medals. With his record breaking swimming abilities, Phelps has come to be known as a personification of precision, slicing up and gushing down the swimming lanes. Diagnosed with ADHD at the age of 9, Phelps has beaten all odds to emerge as a shining example in his personal life and career, proving to be an inspiring role model for ADHD patients worldwide.
But Michael couldn’t have achieved this overwhelming success alone. Debbie Phelps, Michael Phelps’ mother, has been the driving force behind her son’s success, both personally and professionally. With the help of medication, behavior therapy and most importantly, the support of his mother, Michael was able to channel his energies into swimming, becoming the youngest male record holder in modern sports at the age of 15.
Among all modes of treatment, medication therapy is considered to be the best option to treat ADHD. They include both stimulants and non-stimulants. In cases, where stimulants do not work or cause severe side effects, non-stimulants are recommended by doctors. In this context, Strattera (also known as atomoxetin) is the first non-stimulant drug approved by FDA. It is now used for the treatment of ADHD in children aged 6 or older, teens, and adults.
BCC Research recently launched the Forecast model of Strattera®, which provides quantitative data about the pharmaceutical drug, Strattera®. The model will guide potential customers make strategic decision-making regarding future participation in this product sector since it comes off patent in 2017.
BCC Research Strattera® Forecast Model is available in an easily accessible Microsoft Excel spreadsheet covering market demand forecasts for the years 2010 to 2030. Segmentation has been shown in volume (number of patients) and value (U.S. dollars) for the countries like United States, Japan, France, Germany, Italy, Spain, and U.K.
Currently available treatments cannot cure the disorder per se. Instead, they focus on reducing the symptoms of ADHD and improving the individual’s functioning. Treatments include medication, various types of psychotherapy, education or training, or a combination of treatments. Researchers are developing more effective treatments and interventions, and using new tools such as brain imaging, to better understand ADHD and to find more effective ways to treat and prevent it.
Being a psychological disorder, this disorder impacts every aspect of the individual including academic difficulties, social skills problems and parent-child relationships. Therefore, proper behavioural therapy and medication, an environment that is sensitive to the needs of an individual with ADHD, and being aware of the implications of the disorder is vital.
One of the success stories in this context is, undoubtedly, that of Michael Phelps (1985 – present), winner of 22 Olympic medals. With his record breaking swimming abilities, Phelps has come to be known as a personification of precision, slicing up and gushing down the swimming lanes. Diagnosed with ADHD at the age of 9, Phelps has beaten all odds to emerge as a shining example in his personal life and career, proving to be an inspiring role model for ADHD patients worldwide.
But Michael couldn’t have achieved this overwhelming success alone. Debbie Phelps, Michael Phelps’ mother, has been the driving force behind her son’s success, both personally and professionally. With the help of medication, behavior therapy and most importantly, the support of his mother, Michael was able to channel his energies into swimming, becoming the youngest male record holder in modern sports at the age of 15.
Among all modes of treatment, medication therapy is considered to be the best option to treat ADHD. They include both stimulants and non-stimulants. In cases, where stimulants do not work or cause severe side effects, non-stimulants are recommended by doctors. In this context, Strattera (also known as atomoxetin) is the first non-stimulant drug approved by FDA. It is now used for the treatment of ADHD in children aged 6 or older, teens, and adults.
BCC Research recently launched the Forecast model of Strattera®, which provides quantitative data about the pharmaceutical drug, Strattera®. The model will guide potential customers make strategic decision-making regarding future participation in this product sector since it comes off patent in 2017.
BCC Research Strattera® Forecast Model is available in an easily accessible Microsoft Excel spreadsheet covering market demand forecasts for the years 2010 to 2030. Segmentation has been shown in volume (number of patients) and value (U.S. dollars) for the countries like United States, Japan, France, Germany, Italy, Spain, and U.K.
Posts
No comments:
Post a Comment